Zoetis Inc. $ZTS Shares Purchased by Oddo BHF Asset Management Sas

Oddo BHF Asset Management Sas increased its stake in shares of Zoetis Inc. (NYSE:ZTS) by 28.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 47,469 shares of the company’s stock after acquiring an additional 10,622 shares during the period. Oddo BHF Asset Management Sas’ holdings in Zoetis were worth $5,973,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the stock. Global Wealth Strategies & Associates purchased a new stake in Zoetis in the 4th quarter worth approximately $25,000. KERR FINANCIAL PLANNING Corp purchased a new stake in Zoetis in the 3rd quarter worth approximately $31,000. Lodestone Wealth Management LLC acquired a new position in shares of Zoetis in the 4th quarter valued at $30,000. Elyxium Wealth LLC acquired a new position in shares of Zoetis in the 4th quarter valued at $32,000. Finally, Holos Integrated Wealth LLC acquired a new position in shares of Zoetis in the 4th quarter valued at $32,000. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Price Performance

Shares of NYSE ZTS opened at $79.95 on Tuesday. The firm has a 50-day simple moving average of $96.18 and a 200-day simple moving average of $113.83. The stock has a market capitalization of $33.52 billion, a price-to-earnings ratio of 13.26, a price-to-earnings-growth ratio of 1.24 and a beta of 0.75. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80. Zoetis Inc. has a 52 week low of $72.38 and a 52 week high of $166.77.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The firm had revenue of $2.26 billion during the quarter, compared to analysts’ expectations of $2.30 billion. During the same period in the prior year, the company posted $1.48 EPS. The company’s revenue for the quarter was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, equities analysts predict that Zoetis Inc. will post 6.88 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be issued a $0.53 dividend. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.7%. Zoetis’s dividend payout ratio is currently 35.16%.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on ZTS. Argus reiterated a “hold” rating on shares of Zoetis in a research note on Wednesday, May 27th. Citigroup decreased their target price on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a research note on Monday, May 18th. Weiss Ratings cut shares of Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday. Morgan Stanley reiterated an “overweight” rating and issued a $115.00 target price on shares of Zoetis in a research note on Friday, May 15th. Finally, William Blair reiterated an “outperform” rating on shares of Zoetis in a research note on Monday, March 2nd. Six investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Zoetis has a consensus rating of “Hold” and a consensus price target of $133.92.

Insider Activity at Zoetis

In related news, Director Paul Bisaro bought 2,000 shares of the stock in a transaction on Wednesday, May 13th. The stock was bought at an average price of $75.88 per share, with a total value of $151,760.00. Following the completion of the purchase, the director directly owned 27,862 shares in the company, valued at $2,114,168.56. This represents a 7.73% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Frank A. Damelio bought 6,650 shares of the stock in a transaction on Wednesday, May 13th. The shares were bought at an average cost of $75.39 per share, with a total value of $501,343.50. Following the purchase, the director owned 21,458 shares of the company’s stock, valued at $1,617,718.62. This trade represents a 44.91% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last quarter, insiders bought 11,650 shares of company stock valued at $886,384. 0.22% of the stock is owned by company insiders.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.